Journal ArticleDOI
Effect of pegylation on pharmaceuticals
J. Milton Harris,Robert B. Chess +1 more
Reads0
Chats0
TLDR
How PEGylation can result in drugs that are often more effective and safer, and which show improved patient convenience and compliance are reviewed.Abstract:
Protein and peptide drugs hold great promise as therapeutic agents. However, many are degraded by proteolytic enzymes, can be rapidly cleared by the kidneys, generate neutralizing antibodies and have a short circulating half-life. Pegylation, the process by which polyethylene glycol chains are attached to protein and peptide drugs, can overcome these and other shortcomings. By increasing the molecular mass of proteins and peptides and shielding them from proteolytic enzymes, pegylation improves pharmacokinetics. This article will review how PEGylation can result in drugs that are often more effective and safer, and which show improved patient convenience and compliance.read more
Citations
More filters
Journal ArticleDOI
Principles of nanoparticle design for overcoming biological barriers to drug delivery
TL;DR: By successively addressing each of the biological barriers that a particle encounters upon intravenous administration, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.
Journal ArticleDOI
Drug Delivery Systems: Entering the Mainstream
TL;DR: There is considerable interest in exploiting the advantages of DDS for in vivo delivery of new drugs derived from proteomics or genomics research and for their use in ligand-targeted therapeutics.
Journal ArticleDOI
Nanoparticle therapeutics: an emerging treatment modality for cancer
TL;DR: The features of nanoparticle therapeutics that distinguish them from previous anticancer therapies are highlighted, and how these features provide the potential for therapeutic effects that are not achievable with other modalities are described.
Journal ArticleDOI
The dawning era of polymer therapeutics
TL;DR: The successful clinical application of polymer–protein conjugates, and promising clinical results arising from trials with polymer–anticancer-drug conjugate, bode well for the future design and development of the ever more sophisticated bio-nanotechnologies that are needed to realize the full potential of the post-genomic age.
Journal ArticleDOI
The golden age: gold nanoparticles for biomedicine
TL;DR: It is argued that gold nanotechnology-enabled biomedicine is not simply an act of 'gilding the (nanomedicinal) lily', but that a new 'Golden Age' of biomedical nanotechnology is truly upon us.
References
More filters
Journal ArticleDOI
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Michael W. Fried,Mitchell L. Shiffman,K. Rajender Reddy,C. Smith,George Marinos,Fernando L. Gonçales,Dieter Häussinger,Moisés Diago,Giampiero Carosi,Daniel Dhumeaux,Antonio Craxì,A. Lin,Joseph Hoffman,Jian Yu +13 more
TL;DR: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.
Journal ArticleDOI
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Michael P. Manns,John G. McHutchison,Stuart C. Gordon,Vinod K. Rustgi,Mitchell L. Shiffman,Robert Reindollar,Zachary Goodman,Kenneth Koury,Mei Hsiu Ling,Janice K. Albrecht +9 more
TL;DR: In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin, and this randomised trial found that the benefit is mostly achieved in patients with HCV genotype 1 infections.
Journal ArticleDOI
Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
John G. McHutchison,Stuart C. Gordon,Eugene R. Schiff,Mitchell L. Shiffman,William M. Lee,Vinod K. Rustgi,Zachary Goodman,Mei Hsiu Ling,Susannah Cort,Janice K. Albrecht +9 more
TL;DR: In patients with chronic hepatitis C, initial therapy withinterferon and ribavirin was more effective than treatment with interferon alone.
Physicians Desk Reference
TL;DR: In this paper, the authors present a list of manufacturers, product categories, and diagnostic product information, including name, product category, and identification of product categories and attributes, with a focus on medical applications.
Journal ArticleDOI
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
Thierry Poynard,Patrick Marcellin,Samuel S. Lee,Christian Niederau,Gerald S. Minuk,Gaetano Ideo,Vincent G. Bain,Jenny Heathcote,Stefan Zeuzem,Christian Trepo,Janice K. Albrecht +10 more
TL;DR: AnInterferon α2b plus ribavirin combination is more effective than 48 weeks of interferonα2b monotherapy and has an acceptable safety profile and patients with few favourable factors benefit more from extending the duration of combination therapy to 48 weeks.